BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2592856)

  • 1. Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use.
    Massouh M; Jatoi A; Gordon EM; Ratnoff OD
    J Lab Clin Med; 1989 Dec; 114(6):697-9. PubMed ID: 2592856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased heparin cofactor II levels in women taking oral contraceptives.
    Toulon P; Bardin JM; Blumenfeld N
    Thromb Haemost; 1990 Nov; 64(3):365-8. PubMed ID: 2096488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
    Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin cofactor II levels are increased by the use of combined oral contraceptives.
    Mackie IJ; Segal H; Burren T; Gallimore M; Walshe KJ; Robinson G; Machin SJ
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):647-51. PubMed ID: 2133244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
    Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
    Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.
    Andrew M; Mitchell L; Berry L; Paes B; Delorme M; Ofosu F; Burrows R; Khambalia B
    J Clin Invest; 1992 Jan; 89(1):321-6. PubMed ID: 1729278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of a combined oral contraceptive on lactation and growth of the infant].
    Peralta O; Díaz S; Juez G; Herreros C; Casado ME; Salvatierra AM; Miranda P; Croxatto H
    Rev Chil Obstet Ginecol; 1983; 48(5):372-80. PubMed ID: 6681210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.
    Olsson H; Lindahl B; Ranstam J; Borg A; Fernö M; Norgren A
    Anticancer Res; 1987; 7(4B):853-6. PubMed ID: 3674773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oestrogen dose on whole blood platelet activation in women taking new low dose oral contraceptives.
    Norris LA; Bonnar J
    Thromb Haemost; 1994 Dec; 72(6):926-30. PubMed ID: 7740465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The APTT response of pregnant plasma to unfractionated heparin.
    Chunilal SD; Young E; Johnston MA; Robertson C; Naguit I; Stevens P; Galashan D; Oskamp ML; Brennan B; Ginsberg JS
    Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC
    Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral contraceptive risks: a realistic appraisal.
    Bressler R; Durand JL
    Drug Ther (NY); 1979 Oct; 9(10):81-95. PubMed ID: 12279276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weighing the evidence on the pill and breast cancer.
    Johnson JH
    Fam Plann Perspect; 1989; 21(2):89-92. PubMed ID: 2653859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of heparin cofactor II on the antithrombin III activities measured by thrombin methods or factor Xa methods--fundamental studies and clinical studies using the plasma of pregnant women].
    Akai Y; Shiga S; Tohyama K; Shimatsu A; Ichiyama S
    Rinsho Byori; 2000 Sep; 48(9):867-71. PubMed ID: 11051806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of oral contraceptives on protein metabolism.
    Amatayakul K; Laokuldilok T; Koottathep S; Dejsarai W; Prapamontol T; Srirak N; Tansuhaj A; Uttaravichai C
    J Med Assoc Thai; 1994 Oct; 77(10):509-16. PubMed ID: 7745371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral contraceptives and blood platelets].
    Davenas E; Ciavatti M; Poitevin B; Aubin M
    Homeopath Fr; 1985; 73(5):299-305. PubMed ID: 12281246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.